Skip to main content
. 2022 Jan 31;22(2):136–144. doi: 10.1038/s41397-022-00268-6

Fig. 5. Relevant actionable variants in the EMPAR population.

Fig. 5

A Number of carriers of pharmacogenetic markers with PharmGKB Evidence level 1A/1B with regard to cardiovascular indications. Major allele here defined as wild type (W); M: minor allele or actionable variant respectively; NA: information not available; MW: actionable variant/wild type. B Proportions of participants in the complete study population with 1, 2, 3, 4, and ≥5 actionable variants shown in A.